# OnCo record nct05201066 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05201066/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05201066", "NCT05201066" ;
  schema:name "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab."@en ;
  schema:description "A phase 2 trial of Decitabine, Azacitidine and Venetoclax in myelodysplastic syndromes / neoplasms, run by Novartis Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05201066/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05201066> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-02-28" ;
  onco:cancers <https://onco.cc/cancers/mds/> ;
  onco:drugs <https://onco.cc/drugs/decitabine/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/spartalizumab/>, <https://onco.cc/drugs/sabatolimab/> ;
  onco:companies <https://onco.cc/companies/advanced-accelerator-applications/> .